An update on the development of antiviral against Mayaro virus: from molecules to potential viral targets

Mayaro virus (MAYV), first isolated in 1954 in Trinidad and Tobago islands, is the causative agent of Mayaro fever, a disease characterized by fever, rashes, headaches, myalgia, and arthralgia. The infection can progress to a chronic condition in over 50% of cases, with persistent arthralgia, which...

Full description

Saved in:
Bibliographic Details
Published in:Archives of microbiology 2023-04, Vol.205 (4), p.106-106, Article 106
Main Authors: Paschoalino, Marina, Marinho, Mikaela dos Santos, Santos, Igor Andrade, Grosche, Victória Riquena, Martins, Daniel Oliveira Silva, Rosa, Rafael Borges, Jardim, Ana Carolina Gomes
Format: Article
Language:English
Subjects:
Aedes
Aedes aegypti
Alphavirus
Analgesics
Animals
Anti-inflammatory agents
Antigens
Antiviral activity
Antiviral agents
Antiviral Agents - pharmacology
Antiviral Agents - therapeutic use
Aquatic insects
Archives & records
Arthralgia
Biochemistry
Biomedical and Life Sciences
Biotechnology
Cell Biology
Chronic infection
Drug development
Drugs
Ecology
Female
Fever
Genomes
Geographical distribution
Glycoproteins
Humans
Inflammation
Life Sciences
Microbial Ecology
Microbiology
Mini Review
Mosquito Vectors
Mosquitoes
Myalgia
Nonsteroidal anti-inflammatory drugs
Proteins
Serology
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mayaro virus (MAYV), first isolated in 1954 in Trinidad and Tobago islands, is the causative agent of Mayaro fever, a disease characterized by fever, rashes, headaches, myalgia, and arthralgia. The infection can progress to a chronic condition in over 50% of cases, with persistent arthralgia, which can lead to the disability of the infected individuals. MAYV is mainly transmitted through the bite of the female Haemagogus spp. mosquito genus. However, studies demonstrate that Aedes aegypti is also a vector, contributing to the spread of MAYV beyond endemic areas, given the vast geographical distribution of the mosquito. Besides, the similarity of antigenic sites with other Alphavirus complicates the diagnoses of MAYV, contributing to underreporting of the disease. Nowadays, there are no antiviral drugs available to treat infected patients, being the clinical management based on analgesics and non-steroidal anti-inflammatory drugs. In this context, this review aims to summarize compounds that have demonstrated antiviral activity against MAYV in vitro, as well as discuss the potentiality of viral proteins as targets for the development of antiviral drugs against MAYV. Finally, through rationalization of the data presented herein, we wish to encourage further research encompassing these compounds as potential anti-MAYV drug candidates.
ISSN:0302-8933
1432-072X
DOI:10.1007/s00203-023-03441-y